Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 154
- Registration Number
- NCT02426294
- Locations
- 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
Fatty Liver Study in Patients With Type II Diabetes
- Conditions
- Interventions
- First Posted Date
- 2015-02-18
- Last Posted Date
- 2018-07-31
- Target Recruit Count
- 5
- Registration Number
- NCT02365233
- Locations
- 🇺🇸
University of Texas Medical Branch -Galveston, Galveston, Texas, United States
Preventing Squamous Cell Skin Cancer
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 12
- Registration Number
- NCT02347813
Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02342067
- Locations
- 🇺🇸
DaVita Clinical Research, Lakewood, Colorado, United States
Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
- Conditions
- Interventions
- First Posted Date
- 2015-01-15
- Last Posted Date
- 2021-09-14
- Target Recruit Count
- 88
- Registration Number
- NCT02338999
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management
- First Posted Date
- 2014-12-11
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 190
- Registration Number
- NCT02315287
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle
- Conditions
- Interventions
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- University of Nottingham
- Target Recruit Count
- 26
- Registration Number
- NCT02305069
- Locations
- 🇬🇧
David Greenfield Physiology Laboratories, Nottingham, Nottinghamshire, United Kingdom
Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2014-11-27
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Charles Drew University of Medicine and Science
- Target Recruit Count
- 22
- Registration Number
- NCT02303405
- Locations
- 🇺🇸
Charles Drew University of Medicine and Science, Los Angeles, California, United States
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease
- Conditions
- Interventions
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT02284906
Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 20
- Registration Number
- NCT02276365
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.